Affirm's Transformer Underwriting Model Is Incremental, Not a Fix for Valuation and Leverage Risks

What happened

Affirm announced a new transformer-based machine learning model for real-time underwriting, reinforcing its narrative of data and AI advantages. However, this development does not address the core concerns highlighted in the deep value report: the stock trades at approximately 104x trailing earnings and over 200% above a simple DCF-based intrinsic value of ~$24 per share. The company also carries high leverage (net debt/EBITDA ~9x) and depends heavily on securitization and institutional funding, leaving it vulnerable to credit or funding shocks. While the model could theoretically improve underwriting accuracy and reduce losses, there is no evidence yet that it will materially alter the risk profile or economics. Investors should view this announcement as a positive but minor technological evolution rather than a game-changing event that justifies the current valuation.

Implication

The transformer model may enhance Affirm's competitive moat in underwriting, but the moat is already recognized and priced in; the key risks of credit deterioration, funding access, and regulatory pressure remain unchanged. With the stock trading far above intrinsic value and at extreme multiples, even improved underwriting may not be enough to offset downside in a credit or funding crisis. Investors should focus on upcoming credit metrics, ABS issuance costs, and any regulatory developments rather than technological announcements. Absent a substantial reduction in delinquencies or a significant pullback in stock price, the risk/reward remains unattractive for value-oriented investors. A disciplined approach would be to wait for either a meaningful price correction or clear evidence that the new model delivers sustained, peer-beating loss rates.

Thesis delta

The prior thesis of a potential sell remains intact. This news reinforces Affirm's technological differentiation but does not address the primary concerns of extreme valuation, high leverage, and funding dependence. No change to the action recommendation is warranted at this time.